Patent · US Active

Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker

US7972612B2 · kind B2 · utility

2Cited by
5References
2Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 17, 2003
Grant dateJul 5, 2011
Priority date
Expiry dateSep 8, 2026

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor having a novel action and a β-blocker as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with the β-blocker. For the administration mode, each drug can be administered in combination or in mixture.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.